News

Myriad, SOPHiA GENETICS and AstraZeneca team up on prostate cancer genomic score PrGIS

What's the deal? Myriad Genetics and SOPHiA GENETICS announced on 8 October 2026 a collaboration with AstraZeneca to advance PrGIS, a new prostate-cancer-specific genomic instability score. PrGIS measures chromosomal instability linked to homologous recombination deficiency (HRD) — a defect in a cell's DNA-repair machinery that can make tumours sensitive to certain targeted treatments. Under the collaboration, the companies aim to test PrGIS in clinical trials and develop it as a potential companion diagnostic to identify patients who may benefit from precision oncology medicines.

Why it matters: HRD screening is already used in cancers such as ovarian and breast cancer to match patients to PARP inhibitors and other targeted drugs; extending it to prostate cancer could open a new biomarker-driven treatment approach in one of the most common cancers in men. Myriad brings its genomic-testing platform (including its MyChoice companion diagnostics), while SOPHiA GENETICS contributes its clinical data-analysis software and hospital network — a combination that could broaden access to HRD-based testing in prostate cancer.

Read more: PR Newswire, 8 October 2026

More top stories